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Susceptibility to HIV-1 and the clinical course after infection show a substantial heterogeneity between individuals.
Part of this variability can be attributed to host genetic variation. Initial candidate gene studies have revealed
interesting host factors that influence HIV infection, replication and pathogenesis. Recently, genome-wide
association studies (GWAS) were utilized for unbiased searches at a genome-wide level to discover novel genetic
factors and pathways involved in HIV-1 infection. This review gives an overview of findings from the GWAS
performed on HIV infection, within different cohorts, with variable patient and phenotype selection. Furthermore,
novel techniques and strategies in research that might contribute to the complete understanding of virus-host
interactions and its role on the pathogenesis of HIV infection are discussed.
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HIV pathogenesisIntroduction
There is considerable heterogeneity in HIV-1 suscepti-
bility and in disease progression rates after infection.
Certain people are relatively resistant to HIV-1 infection
and remain uninfected despite multiple exposures to
HIV-1, while others are infected upon first exposure.
After seroconversion, some individuals progress to AIDS
in as little as 2 years, while others remain symptom-free
for more than 15 years. This variation between indivi-
duals is determined by both viral and host factors.
The emergence of HIV-1 variants that use coreceptor
CXCR4 rather than CCR5 in the course of infection is
associated with an accelerated CD4+ T-cell decline and
more rapid progression to AIDS [1,2]. Other evidence
that viral factors may influence the clinical course of
HIV-1 infection comes from a cohort of long-term non-
progressors (LTNPs) who were all infected with an HIV-1* Correspondence: h.schuitemaker@amc.uva.nl
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distribution, and reproduction in any mediumvariant that was attenuated due to a deletion in the viral
nef gene [3].
The first polymorphisms in host genetic factors that
affected HIV-1 infection and disease were determined
using candidate gene studies, in which genetic variants
of host factors that were already known or suspected to
play a role in HIV-1 pathogenesis and immune regula-
tion were tested for association with HIV-1 infection
and/or disease progression. These studies identified sev-
eral important host polymorphisms associated with
HIV-1 infection and pathogenesis [4-14]. The human
leukocyte antigen (HLA) type is a strong example of a
host factor that is associated with HIV-1 disease course.
HLA-B*5701 and HLA-B27 are more prevalent among
LTNPs whereas HLA-B35 is associated with an acceler-
ated progression to AIDS [15-17]. Another important
host factor polymorphism is a 32 basepair deletion in
CCR5 (CCR5Δ32), the major coreceptor for HIV-1. This
deletion, which results in a truncated protein product
that is no longer expressed on the cell surface, provided
nearly complete protection against HIV-1 infection in
individuals homozygous for this deletion [18-20]. Indivi-
duals carrying the heterozygous CCR5Δ32 genotype
have sufficient CCR5 expression on the cell surface totral Ltd. This is an Open Access article distributed under the terms of the
/creativecommons.org/licenses/by/2.0), which permits unrestricted use,
, provided the original work is properly cited.
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is associated with delayed disease progression after HIV-
1 infection [18,21,22].
In the case of CCR5, the association between the gen-
etic polymorphism and disease progression has even
resulted in the development of new antiviral strategies to
block CCR5 in HIV-1 infected individuals [23]. These
developments illustrate the potential of host genetic re-
search to combat HIV-1 infection and AIDS. However,
even when combined, these genetic variations together
still only explained a small fraction of the variability of
HIV-1 control between individuals.
The more recent genome-wide association studies
(GWAS) offer a hypothesis-free analysis to scan the
complete human genome for additional factors without
a priori knowledge about their role in complex diseases.
Following the completion of the human genome se-
quence in 2003 [24], the HapMap project was launched
[25] in which commonly occurring genetic variations
were identified along the complete genome and across
several populations. These mostly single DNA mutations
were called single-nucleotide polymorphisms (SNPs). In
most of the genome, combinations of SNPs appear to be
found together in blocks with strong linkage disequilib-
rium (LD), which gives the opportunity to cover almost
the whole genome on the chips used in GWAS, by
selecting “tagSNPs” that represent the LD blocks [26]. In
this review, we will discuss GWAS performed on HIV-1,
focusing on the differences in cohorts and phenotypes
used.
Review
Genome-wide association studies on HIV-1
Host genetic factors that associate with viral load control
The first reported GWAS was performed on 486 indivi-
duals from the Euro-CHAVI cohort, and used HIV RNA
viral load at set point as phenotype, which is known to
be predictive for disease progression. (see Table 1 for an
overview of all published GWAS up to date) [27]. In the
association analysis, using linear regression, two loci
were genome-wide significantly associated with viral
load at set point. Without an a priori hypothesis, a strin-
gent correction for multiple tests in GWAS is required
to avoid false-positive errors. The current standard for
genome-wide significance in GWAS is a P-value below
5x10-8. One of these loci is tagged by SNP rs2395029
near the HLA complex 5 gene (HCP5), a gene that is
localized within the MHC class I region. SNP rs2395029
is in nearly absolute LD with HLA-B*57, which was
already known to be protective against disease progres-
sion as described above. The other SNP, rs9264942, is
located 35kb from the HLA-C gene. It was shown that
the variation within the 3’ UTR region of HLA-C regu-
lates binding of the microRNA hsa-miR-148 to its targetsite, resulting in differential expression of the HLA-C
gene [28,29]. Despite the fact that the HCP5 SNP and
−35 HLA-C SNP were in moderate LD, Fellay et al.
showed an independent effect of each of these variants
on the viral load set point variation between individuals.
This first GWAS additionally identified a set of seven
SNPs that were in high LD and located close to ring fin-
ger protein 39 (RNF39) and zinc ribbon domain-
containing protein 1 (ZNRD1), to be associated with
progression to CD4+ T cell count below 350 cells/ml
[27]. The replication study by Catano et al. [30] showed
that the causal effect of these SNPs on HIV-1 disease
progression might be because of a very strong LD be-
tween these SNPs and HLA-A10.
In a follow-up study, Fellay et al. [33] performed a
GWAS on an extended population (n = 2362) to identify
additional genetic variants that could explain the variabil-
ity of HIV-1 control between individuals. As expected, this
study confirmed the association of the HCP5 SNP
(rs2395029, P = 4.5 x 10-35) and the −35 HLA-C SNP
(rs9264942, P = 5.9 x 10-32) with viral load at set point.
Next to these already known variants, the authors identi-
fied other, independent loci in the MHC that were asso-
ciated with viral load control. For example rs9468692,
located in the 3’ region of the TRIM10 gene, and the non-
synonymous coding SNP rs8192591, located in the 9th
exon of the NOTCH4 gene.
Dalmasso et al. [31] also used viral load as a disease
phenotype in their GWAS, but evaluated plasma HIV-
RNA during primary infection rather than at set point.
This study analyzed 605 seroconverters in a case–con-
trol study, comparing 45 long-term HIV controllers, with
an RNA viral load below 400 copies/ml for more than
10 years, with the rest of the HIV-infected individuals.
The protective allele of SNP rs10484554, located in the
region between HLA-C and HLA-B, was genome-wide
significantly (P = 3.58 x 10-9) over-represented among
the long-term HIV controllers. These authors identified
HCP5 rs2395029 to be most strongly associated with HIV-
1 DNA levels in the first patient samples drawn at the time
of enrolment during primary infection (P = 6.72 x 10-7).
These HIV-1 DNA levels were considered as a marker of
the HIV reservoir in their seroconverters. This SNP was
also associated with HIV controller status, thereby confirm-
ing the results from the first GWAS by Fellay et al.
Viral load was also used as the phenotype in the multi-
national HIV Controllers study [35]. This large cohort of
HIV-infected individuals was divided into elite and
viremic controllers (n = 1526), which are seropositive
individuals who are able to control viral load to levels
below 50 or 2,000 copies of viral RNA/ml plasma re-
spectively, and HIV-1 progressors (n = 2648), who failed
to ever control viremia without therapy. Over 300 SNPs
were identified to be genome-wide significantly associated
Table 1 Description of GWAS on HIV infection and the most interesting signals discovered
cohort year Phenotype Most important
association
P-value Validation ethnicity ref
CHAVI 2007 RNA VL setpoint HCP5 (rs2395029) 9.4E-12 Significant, confirmed Caucasian [27]
−35 HLA-C (rs9264942) 3.8E-09 Significant, confirmed
CD4 T cell decline ZNRD1 (rs9261174) 3.9E-07 Confirmed
ANRS PRIMO 2008 plasma HIV RNA primary
infection
HCP5 (rs2395029) 9.3E-07 Significant, confirmed Caucasian [31]
cellular HIV DNA primary
infection
HCP5 (rs2395029) 6.7E-07 Significant, confirmed
GRIV 2009 long-term nonprogression HCP5 (rs2395029) 6.8E-10 Significant, confirmed Caucasian [32]
C6orf48 (rs9368699) 5.3E-07 Putative
Euro-CHAVI, MACS 2009 RNA VL setpoint HCP5 (rs2395029) 4.5E-35 Significant, confirmed Caucasian [33]
−35 HLA-C (rs9264942) 5.9E-32 Significant, confirmed
GRIV 2009 rapid progression PRMT6 (rs4118325) 6.1E-07 Putative Caucasian [34]
SOX5 (rs1522232) 1.8E-06 Putative
International HIV
controllers study




−35 HLA-C (rs9264942) 2.8E-35 Significant, confirmed
HCP5 (rs2395029) 9.7E-26 Significant, confirmed
MICA (rs4418214) 1.4E-34 Significant





HS3ST3A1 (rs8069770) 3.8E-05 Putative African [36]
MACS 2010 progression to AIDS PROX1 (rs17762192) 6.2E-07 Confirmed Caucasian [37]
DoD HIV NHS and
MACS
2010 RNA VL setpoint HLA-B*5703 5.6E-10 Significant, confirmed African [38]
GRIV, MACS, ACS 2010 long-term nonprogression
(VL > 100 cp/ml)
CXCR6 (rs2234358) 9.7E-10 Significant, confirmed Caucasian [39]
CHAVI, Malawi 2011 HIV acquisition African [40]





2011 in vitro HIV-1 replication in
macrophages
DYRK1A (rs12483205) 2.2E-05 Putative Caucasian [42]
ACS 2011 progression to AIDS,
or AIDS-related death
AGR3 (rs152363) 3.5E-06 Putative Caucasian [43]
Thailand 2011 Nevaripine tolerance CCHCR1 (rs1265112) 1.2E-08 Significant Asian [44]
African serodiscordant
couples cohort
2011 HIV acquisition African [45]
VL; viral load.
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the MHC gene region on chromosome 6. Only four of
these SNPs were independently associated with viremic
control: the already known SNPs −35 HLA-C (P = 2.8 x
10-35) and HCP5 rs2395029 (P = 9.7 x 10-26), and two novel
SNPs, rs4418214, located near MICA (P = 1.4 x 10-34), and
rs3131018 in PSORSIC3 (P = 4.2 x 10-16), a gene that has
been implicated in psoriasis. Interestingly, the authors iden-
tified several specific amino acids in the HLA-B peptide
binding groove to be even more strongly associated with
viral load control than any SNP found in the GWAS, or
any of the HLA alleles.Host genetic factors that associate with HIV-1 disease
progression
Two GWAS were performed in the Genomics of Resist-
ance to Immunodeficiency Virus (GRIV) cohort to look
for genetic associations with extreme phenotypes in HIV-
1 infection in either LTNPs [32] or rapid progressors (RP)
[34]. The nonprogression GRIV GWAS compared 275
LTNPs to a control group of 1352 seronegative individuals
and found HCP5 rs2395029 to be most strongly asso-
ciated with nonprogression after HIV-1 infection (P = 6.8
x 10-10). Mainly associations with genetic variation in
chromosome 6 were found and this GWAS again
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HCP5 and the ZNRD1 locus identified by the EURO-
CHAVI cohort. More recently, this GWAS was reanalyzed
to specifically identify genetic variants that associate with
LTNP without elite control of the viral load [39]. To this
end, the authors compared 697 uninfected individuals
with 186 LTNPs, excluding elite controller patients with a
viral load below 100 copies/ml. SNP rs2234358 in the
CXCR6 gene was identified to be associated with LTNP
and this association could be replicated in three independ-
ent European studies (P = 9.7 x 10-10).
The only genome-wide analysis of RP to date [34]
revealed several interesting loci outside the MHC region
in a case–control study of 85 HIV-1-infected patients
who had experienced rapid disease progression and who
were compared with 1352 seronegative individuals. SNPs
rs4118325 (P = 6.1 x 10-7), in the vicinity of PRMT6 and
rs1522232 in SOX5 (P = 1.8 x 10-6) were amongst the
top SNPs that were associated with rapid progression
after HIV-1 infection. These associations were, however,
not significant after correction for multiple testing. The
exact potential mechanism of action for these two SNPs
is unknown. Although analysis of RP yields unique loci,
these individuals are underrepresented in most cohorts.
This low number of RP could be an explanation for the
lack of genome-wide significant signals, and indicates
the difficulty of replicating signals in other RP cohorts.
A multi-stage GWAS in US seroconverters compared
RP (n = 51), moderate progressors (n = 57) and LTNPs
(n = 48) [37]. Genetic variation rs17762192, upstream of
PROX1, a negative regulator of IFN-γ expression in T
cells [46], was associated with slower progression to
AIDS (P = 6.2 x 10-7). Although this SNP upstream of
PROX1 was not genome-wide significantly associated
with slower progression to AIDS, the loci could be repli-
cated in an independent population of 590 HIV-infected
seroconverters.
Troyer et al. [41] identified a cluster of SNPs in the
gene PARD3B to be associated with a delayed survival
time to clinical AIDS (P = 3.4 x 10-9) in a GWAS
amongst US seroconverters (n = 755). One of the
PARD3B variants in this cluster could be confirmed in
two European cohorts of rapid progressors. PARD3B
interacts with members of the SMAD family, which are
known to interact directly with HIV-1 [47]. The HCP5
rs2395029 signal was not found to be associated with
survival time to clinical AIDS in this cohort.
Another GWAS on HIV-1 disease progression was
performed in the Amsterdam Cohort Studies (ACS) [43].
In this study in 404 HIV-infected individuals, the associ-
ation of SNPs with survival time to AIDS-diagnosis and
AIDS-related death was tested. Albeit not genome-wide
significant, SNP rs152363 showed a tendency to associ-
ation with disease progression after HIV-1 infection inboth the ACS and the GRIV cohort (P = 3.5 x 10-6). Fur-
thermore, this GWAS showed that in the ACS the
HCP5 rs2395029 was also significantly associated with
delayed progression to AIDS and AIDS-related death, al-
though the effect was notably reduced when viral load at
set point was included as a covariate in multivariate ana-
lysis [48].
Results from GWAS on disease progression show that
replication in cohorts with alternative phenotypes has
proven to be challenging. Moreover, not many prospect-
ive seroconversion cohorts exist that have sufficient fol-
low up time between the moment of HIV-1 infection
and disease progression, which complicates these sur-
vival studies.
GWAS in African populations
Human genetic studies in disease in general have been
focusing almost exclusively on individuals of European
ancestry. Until 2011 more than 75% of studies in the
catalog of published GWAS were analyzing individuals
from European ancestry [49]. Remarkably, less than 5%
of the GWAS were focusing on individuals from African
descent. For HIV studies this is discouraging, since the
HIV-infection prevalence rate is particularly alarming in
sub-Saharan Africa (http://unaids.org/globalreport). An
obvious reason for this inequality in population coverage
in GWAS is the availability of study populations with
DNA samples and documented phenotypes. In addition,
African populations are characterized by lower levels of
LD [50], which has led to poor coverage of the whole-
genome by proxy SNPs on the initial chips used in
GWAS. Because of this uneven prevalence of European
ancestry in GWAS, and the different genetic make-up of
other populations, reflected in differences in HLA class I
allele frequencies and in LD between populations, associa-
tions of genetic variations that were identified in Caucasian
HIV-infected individuals can be absent from other popula-
tions. Indeed HCP5 rs2395029 was not found to be
associated with viral load at set point in an African
population [51].
The first published GWAS in a non-European popula-
tion searched for associations with more than 500,000
SNPs with viral load at set point in 515 African Americans
[38]. Although no loci were genome-wide significantly
associated with viral load at set point, one of the strongest
associations was a SNP tagging the HLA-B*5703 allele.
Individuals carrying the HLA-B*5703 allele, have a signifi-
cantly lower viral load at set point (P = 5.6 x 10-10),
thereby again emphasizing the important association be-
tween HLA-B*57 and the control of viral load after HIV
infection, both in individuals of African and European
ancestry.
In sub-Saharan Africa, children are infected with HIV
predominantly through mother-to-child transmission
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Malawi cohort to identify the genetic host factors asso-
ciated with vertical transmission of HIV. In this study,
HIV-negative (n = 126) and positive (n = 100) children
from HIV-infected mothers, were compared. The top
signal (rs8069770) was not significant after correction
for multiple testing (P = 3.79 x 10-5). This could be due
to limited sample size, causing the study only to be pow-
ered to detect large genetic effects. SNP rs8069770 is
located within HS3ST3A1, a gene involved in heparin
sulfate biosynthesis, which interestingly is very abun-
dantly expressed in the placenta. In another population
of individuals from Malawi, a country with high preva-
lence of HIV-1 infection, a GWAS was performed to iden-
tify host determinants of HIV-1 susceptibility [40].
Unfortunately, no single SNP yielded a significant P-value
after correction for multiple testing, when the authors
compared 848 high-risk seronegatives with 531 HIV-1
seropositive individuals. Failing to detect a genome-wide
significant signal could be due to the difficulty to quantify
the level of HIV-1 exposure in this population. Although
the studied individuals are assumed to be in a high-risk
category as they are attending STI clinics in a region with
a high HIV-1 prevalence and incidence, there were no ac-
tual data collected on exposure details (e.g. number of
partners and type of sexual contacts). Furthermore, HIV-1
susceptibility can be strongly influenced by other factors,
like circumcision status of male partner, concurrent STIs
and viral load level of the donor.
A recent GWAS selected participants from two
cohorts of African HIV-1 serodiscordant heterosexual
couples [45], thereby increasing the probability that the
HIV-1 negative partners have a risk for HIV-1 acquisi-
tion. In this study 496 HIV-1 infected individuals were
compared to 302 matched HIV-1 uninfected individuals
with similar documented HIV-1 exposure. Nevertheless,
after correction for multiple testing, no SNPs were sig-
nificantly associated with HIV-1 susceptibility, or with
viral load at set point among the subset of HIV-1
infected participants.Alternative phenotypes in GWAS
Most GWAS on HIV infection have focused on viral load
control and disease progression. However, alternative phe-
notypes might be interesting to identify additional host gen-
etic factors for HIV replication and pharmacogenomics.
We performed a genetic association analysis on in vitro
HIV-1 susceptibility of primary monocyte-derived macro-
phages [42]. The top signal identified in this study, while
not genome-wide significant, was rs12483205, a SNP in-
tronic of DYRK1A (P = 2.2 x 10-5). This SNP appeared to
be associated with HIV-1 disease progression as well in
two independent cohort studies.The use of antiretroviral drugs has been associated
with severe toxicities, including hypersensitivity reactions,
neurotoxicity and liver damage [52,53]. Several candidate
gene studies on the association between genetic determi-
nants of people infected with HIV-1 and clinical toxicity
resulting from different antiretroviral drugs have been per-
formed. The study by Chantarangsu et al. [44] was the
first to conduct a GWAS on therapy-side effects in HIV-
infected patients. The study was performed in 72 HIV-
infected Thai patients with nevaripine-induced rash,
compared with 77 nevaripine-tolerant patients, and candi-
date genes were followed-up in an additional group of
patients. SNPs rs1265112 and rs746647, within coiled-coil
a–helical rod protein1 (CCHCR1) on chromosome 6, were
found to be significantly associated with susceptibility to al-
lergic skin reactions after Nevaripine use (P = 1.2 x 10-8).
Since the CCHCR1 gene is located close to both HLA-B
and HLA-C locus, the association with rash might be
explained by LD between CCHCR1 and HLA-B*3505, a
previously identified genetic marker for nevaripine-induced
rash [54].
Discussion
The first GWAS on HIV infection identified variants in
the HLA-region to be most dominantly associated with
viral load at set point [27], which was successfully repli-
cated in other cohorts [30-33,35], using viral load con-
trol and disease progression as phenotypes. GWAS that
used clinical disease progression as a phenotype, such as
LTNP, survival time to AIDS-diagnosis and AIDS-
related death, identified additional genetic variants out-
side the HLA-region [32,34,37,39,41,43]. However, not
all of these signals could be replicated in other studies
and need confirmation. Multiple determinants may ac-
count for the observed variability in results from differ-
ent GWAS, especially those not using viral load at set
point. For example, variability in the phenotype studied,
differences in the genotyping platform that was used, an-
cestry of the study population, gender, transmission
route of infection and choices of statistical tests may in-
fluence the outcomes of these studies. Furthermore, the
number of identified host factors involved in HIV infec-
tion up to now explains only a small fraction of the
observed heritability. Several explanations for this “miss-
ing heritability” have been proposed such as additional
common variants of small effect, low frequency variants
(MAF < 5%), which have not been covered well by
current GWAS, and epigenetic effects. Data from the
1000 Genomes Project (http://www.1000genomes.org)
could help to identify additional associated rare variants.
The 1000 Genomes Project aimed to sequence the full
genome of approximately 2500 individuals, not only
Caucasian individuals but also from African populations
from Malawi, the Gambia and Ghana. These sequences
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ome sequence variation and a further increase in sample
size will likely also reveal new genetic variants.
By combining clinical data from all cohorts that have
longitudinal data, a large sample set will be created
which will give the opportunity to identify novel poly-
morphisms outside the HLA-gene region that have a
small effect, a low-frequency, or a recessive association
thereby explaining only a marginal portion of the
observed variance. The International HIV Acquisition
Consortium (IHAC) has initiated the collection of longi-
tudinal clinical data from all cohorts that have GWAS
data available [55]. Imaginably, it will be a challenge to
combine all of the clinical data that were collected by
the different cohorts. Other opportunities lay in more
in-depth analyses of the available GWAS data, thereby
focusing on pathway analysis and gene-gene interactions
or by combining GWAS data with other genome-scale
data sets, such as RNAi screens or gene expression pro-
filing. These analyses may support the discovery of add-
itional variants that did not survive the stringent
multiple testing correction thresholds in the discovery
studies due to limited power.
Advances in sequencing technologies will enable
whole-genome sequencing (WGS) to rapidly develop
and overtake the position of GWAS in genomic re-
search. Sequencing the complete genome of cases will
make it possible to capture the rare variants that might
be an explanation for the missing heritability in common
diseases and directly identify the causal variant.
Until WGS is inexpensive enough to be used for large
sample sizes, careful selection of individuals is essential.
One approach involves the selection of individuals from
each side of the extremes of the phenotype distribution.
For HIV-1, the sequencing of the complete genome of
hemophiliacs who are known to be highly exposed to
HIV-1, but who have remained uninfected has been
initiated [56]. Still many technical challenges in WGS
need to be overcome. Analysis techniques need to be
developed in order to cope with the millions of variants
that are identified per genome. Moreover, accurately
coding all of the small insertions and deletions is a tre-
mendous challenge.
Whole-exome sequencing, a strategy to selectively se-
quence the coding regions, can be a more cost-effective
alternative to identify host genetic markers that are asso-
ciated with disease. However, there are drawbacks to this
technique, as only a small number of SNPs that are asso-
ciated with traits are located in, or occur in, high LD
with protein coding regions of genes. The vast majority
of trait-associated SNPs fall in intergenic regions and
noncoding introns [49,57].
The shift of genetic research from GWAS to WGS
or exome sequencing might be a particularly positivedevelopment for genomics in African populations,
since the causal variants are genotyped directly, with-
out the need for high LD structures. Thereby, a smal-
ler sample size might be needed to identify rare, causal
variants, making it possible to collect smaller amounts
of samples from individuals from different subpopula-
tion structures throughout the African continent.
Conclusions
Several host genetic determinants of HIV-1 infection
and pathogenesis have been identified in the last decen-
nia, either by the classical candidate-gene approaches or
in the last four years with the help of GWAS. In all these
studies, variants in the HLA-region and the coreceptor
CCR5 were the most consistent and with the largest ef-
fect size. While these polymorphisms may have a large
effect on the disease course in the individual, these gen-
etic markers were only able to explain a small fraction of
overall observed differences in HIV-1 infection and dis-
ease progression in the population. The missing genetic
variations may be identified by combining GWAS data
sets of cohorts to increase power and by looking into
additional phenotypes. Furthermore, in the next couple
of years the use of whole-genome sequencing will most
likely allow the identification of novel rare variations
that are associated with HIV-1 susceptibility and disease
progression and the unraveling of pathways that are
causally involved in these phenotypes. Hopefully, the on-
going genetic research may contribute substantially to
the understanding of the pathogenesis of HIV-1 infec-
tion and thereby lead to the development of new strat-
egies to combat the AIDS epidemic worldwide.
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